32.33
0.66 (2.07%)
| Previous Close | 31.67 |
| Open | 31.72 |
| Volume | 902,967 |
| Avg. Volume (3M) | 1,208,310 |
| Market Cap | 5,966,247,936 |
| Price / Earnings (Forward) | 19.46 |
| Price / Sales | 7.44 |
| Price / Book | 5.76 |
| 52 Weeks Range | |
| Earnings Date | 11 Nov 2025 |
| Profit Margin | -29.95% |
| Operating Margin (TTM) | -25.97% |
| Diluted EPS (TTM) | -1.18 |
| Quarterly Revenue Growth (YOY) | 107.50% |
| Total Debt/Equity (MRQ) | 35.65% |
| Current Ratio (MRQ) | 5.20 |
| Operating Cash Flow (TTM) | -263.30 M |
| Levered Free Cash Flow (TTM) | -202.32 M |
| Return on Assets (TTM) | -8.77% |
| Return on Equity (TTM) | -20.00% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Legend Biotech Corporation | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | 1.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.0 |
| Average | 1.38 |
|
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 1.31% |
| % Held by Institutions | 47.92% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Matthews International Capital Management Llc | 30 Sep 2025 | 1,028,447 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 83.00 (Morgan Stanley, 156.77%) | Buy |
| Median | 76.00 (135.11%) | |
| Low | 60.00 (HC Wainwright & Co., 85.62%) | Buy |
| Average | 72.40 (123.98%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 34.58 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 17 Oct 2025 | 60.00 (85.61%) | Buy | 31.96 |
| JP Morgan | 09 Oct 2025 | 76.00 (135.11%) | Buy | 32.22 |
| 25 Aug 2025 | 78.00 (141.30%) | Buy | 34.60 | |
| Cantor Fitzgerald | 27 Aug 2025 | 66.00 (104.18%) | Buy | 34.72 |
| Morgan Stanley | 12 Aug 2025 | 83.00 (156.77%) | Buy | 36.99 |
| RBC Capital | 12 Aug 2025 | 77.00 (138.21%) | Buy | 36.99 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 14 Oct 2025 | Announcement | Cabaletta Bio Announces Appointment of Steve Gavel as Chief Commercial Officer and Award of Inducement Grant |
| 26 Aug 2025 | Announcement | Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference |
| 18 Aug 2025 | Announcement | Legend Biotech Appoints Carlos Santos as Chief Financial Officer |
| 11 Aug 2025 | Announcement | Legend Biotech Reports Second Quarter 2025 Results and Recent Highlights |
| 28 Jul 2025 | Announcement | Legend Biotech to Host Investor Conference Call on Second Quarter 2025 Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |